New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
08:08 EDTCORICorium 6.5M share IPO priced at $8.00
The deal size was increased to 6.5M shares from 5.5M shares and priced below the $10.00-$12.00 range. Jefferies and Leerink acted as joint book running managers for the offering.
News For CORI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2016
16:07 EDTCORICorium reports Q1 EPS (42c), consensus (35c)
Reports Q1 revenue $7.54M, consensus $9.49M.
February 4, 2016
07:32 EDTCORICorium price target raised to $20 from $17 at Leerink
Subscribe for More Information
February 3, 2016
16:06 EDTCORICorium reports topline interim results from Phase 1 study of Corplex Donepezil
Corium announced positive topline interim results from a Phase 1 clinical study designed to evaluate the pharmacokinetics, or PK, safety and tolerability of the Corplex Donepezil transdermal delivery system for the treatment of mild, moderate and severe dementia of the Alzheimer's type. Donepezil is the leading acetylcholinesterase inhibitor approved by the FDA for daily use in oral tablets and disintegrating tablets for the treatment of Alzheimer's disease. Corium's product candidate is designed for sustained and controlled delivery of the drug in a convenient, once-weekly dosage form, and incorporates its Corplex technology, which Corium developed to enable sustained transdermal delivery of a wide range of drugs. The purpose of the Phase 1 study was to evaluate the pharmacokinetics, safety and tolerability of once-weekly, single-dose Corplex Donepezil in healthy volunteers aged 50-80, compared to Eisai's Aricept once-daily oral tablet taken for seven consecutive days. After a single application of the once-weekly Corplex Donepezil patch, plasma concentrations approached steady state at day 7. The average plasma concentration on day 7 with Corplex Donepezil was higher than the comparator, 5 mg oral Aricept, and was approximately 70% of the expected plasma concentration of 10 mg oral Aricept. PK and statistical projections for subsequent weeks of therapy at steady state predict a highly similar exposure between once-weekly Corplex Donepezil and continued daily oral administration of Aricept. Sustained and controlled delivery of donepezil was demonstrated in the plasma concentrations of all subjects treated with once-weekly Corplex Donepezil, supporting the feasibility of a convenient once-weekly dosing regimen, as compared to daily oral administration. Subjects treated with once-weekly Corplex Donepezil experienced acceptable skin tolerability and no systemic adverse events unique to transdermal delivery. Results support advancing Corplex Donepezil into further clinical development, which will include optimizing the patch for a once-weekly administration delivering 10 mg/day.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use